Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Neoplasms 1Lung Neoplasms 1Intestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Ductal 1Bronchial Neoplasms 1Breast Neoplasms 1Advanced Non-small Cell Lung Cancer 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Nivolumab 2rofecoxib 1paclitaxel poliglumex 1nazartinib 1atezolizumab 1Rosuvastatin Calcium 1RO5126766 1Pemetrexed 1Midazolam 1Gemcitabine 1Food 1Esomeprazole 1Dabigatran 1Cisplatin 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Non-small Cell Lung Cancer × nazartinib × Clear all
NCT02108964 2024-12-11

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Novartis

Phase 1/2 Completed
225 enrolled 31 charts
Thoracic

Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡